Novartis scored a major patent victory for its multiple sclerosis drug, Gilenya, this week. A federal appeals court on Tuesday upheld a dosage regimen patent for the sphingosine 1-phosphate receptor modulator, granting Novartis a permanent injunction against generic challenger HEC Pharma. The patent is currently set to expire in 2027. For the treatment of multiple sclerosis, 25% of all insured lives have unrestricted access to Gilenya under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 1/5/2022